BGI Forms Partnership With Genoks In Field Of Non-Invasive Prenatal Testing Advancing Reproductive Health Services In Turkey

BGI, one of the world’s largest genomics organizations, and Genoks, a leading Turkish genetics company committed to providing accurate clinical diagnoses and biological research services, today jointly announced that they have entered an exclusive collaborative agreement.

Under the terms of the agreement, BGI will transfer its science and technology in the field of non-invasive prenatal testing enabling Genoks to start in-country sequencing services as part of its provision of the NIFTY® test in the Turkish market. Utlilizing its well-developed distribution network, Genoks will be able to provide the NIFTY® test nationwide with significantly faster result turnaround times than other NIPT tests which require samples to be sent abroad for analysis.

The NIFTY® test is a highly accurate non-invasive prenatal test that detects the risk of certain trisomy conditions, such as Down syndrome, Edwards Syndorme and Patau Syndrome, from as early as week 10 of pregnancy. NIFTY® works by using Next Generations Sequencing technology to analyze fetal DNA, which circulates in the mother’s blood during pregnancy. The test therefore reduces the rate of unnecessary amniocenteses, exposing fewer women to the risk of miscarriage associated with this

Mr. Eren AKDENIZ, Director of Genoks, comments, “Although we have been working with BGI for a few years, the NIFTY technology transfer agreement will take our level of cooperation to the next level. There are more than 1.2 million births in Turkey each year and we believe that the NIFTY® test has a vital role to play in helping improve pregnancy health and reproductive choices for Turkish parents. Our chairman, Mr. Özden BOSTAN, is committed to this goal and long term collaboration with BGI.’’

BGI Europe’s Director, Dr. Ning Li, adds, “We are delighted to collaborate with Genoks in order to help improve healthcare for pregnant women and their families in Turkey. We expect our joint efforts will yield great achievements and we look forward to a successful and lasting collaboration.’’

About BGI

BGI is one of the world’s largest genomics organizations. Relying on proprietary bioinformatics and analytically-validated methods to detect clinically-relevant genetic changes, BGI is proud to offer a comprehensive range of transformative genetic tests, which provide highly accurate results with high sensitivity and specificity.

BGI’s extensive industry experience, proven workflows and global support network allow testing to be seamlessly integrated in to existing clinical practice for partners worldwide.


About Genoks

Genoks was founded in 2008 with the goal of supporting individual and institutional scientific research and development on an international platform.

Genoks cooperates with public institutions including TUBITAK ( The Scientific & Technological Research Council of Turkey ) and KOSGEB ( Republic of Turkey, Small & Medium Enterprises Development Organizations ) in the fields of Molecular Biology, Biotechnology, Molecular Microbiology and Food Microbiology.

Using its own strengths in Research and Development and employee expertise, Genoks works with private partners in order to bring innovative and cutting edge genetic technologies to the Turkish market place.

The company has offices in Ankara and Istanbul and provides its services nationally through a well-developed distribution network.


BGI Europe

Ole Maaløes Vej 3, DK-2200 Copenhagen N
+45 7026 0806

Genoks Molecular Biology & Biotechnology

Aziziye Mahallesi, Cinnah Caddesi,

No: 64/B

06680, ÇANKAYA

Ankara / TÜRKİYE

+90 312 229 78 59